Artificial Intelligence In Cancer Treatments: Improving Accuracy And Efficiency In Oncology
Regulatory and Ethical Oversight for AI in Oncology Across Canada
Regulatory review of AI systems used in oncology is conducted under Canadian federal legislation, including the Food and Drugs Act, and administrative guidelines provided by Health Canada and provincial authorities. Approval pathways for AI medical devices require demonstration of safety, reliability, and clinical benefit, with post-market monitoring for emerging risks or performance issues.
Ethical considerations in Canadian AI oncology projects focus on transparency, non-discrimination, and patient autonomy. Institutions carrying out AI research or implementation must gain approval from research ethics boards (REBs) and ensure that patient consent processes are followed where necessary. When dealing with data from across multiple jurisdictions, harmonization with privacy and data protection standards like the Personal Health Information Protection Act (PHIPA) is typical.
AI systems are generally viewed as decision-support tools under Canadian regulation, not as independent clinical actors. Their outputs must be interpreted by licensed healthcare professionals, and mechanisms are in place to report and investigate any concerns about algorithmic recommendations. Canadian oncologists are encouraged to engage with AI system providers about oversight processes and limitations of system outputs.
Bayesian assessment, model retraining, and ongoing validation are part of the regulatory and professional framework in Canadian cancer centres. This helps ensure that AI tools remain up to date, accurate, and relevant to evolving clinical needs and population demographics. Oversight bodies typically require that AI implementers disclose the nature, limits, and provenance of algorithms to both clinicians and, where relevant, patients.